Patient empowerment and co-creation in cancer research – the only way to go – Mark Lawler (Queen’s University Belfast, UK) 

Putting patients first – the FDA perspective – Vishal Bhatnagar (FDA, US)

The Added Value of Patient Engagement in Early Dialogue at EMA: Scientific Advice as a Case Study – Maria Mavris (EMA, NL)

Evidence Based Advocacy and the impact of patient evidence on decision-making processes – Ananda Plate (Patvocates, DE) 

Making scientific research understandable and accessible to the (cancer) patient and caregiver community – Pooja Merchant (Bayer, US) – This speaker did not consent for her slides to be shared

Early access for patients through conditional reimbursement schemes – Haiko Bloemendal (Radboud University Medical Center, NL)

Patient Perspective on early access – Stefan Gijssels (Patient Expert Center, BE)

Driving a data informed patient relevant agenda – lessons from DATA-CAN, the UK’s Health Data Research Hub for Cancer – Mark Lawler (Queen’s University Belfast, UK)

Data privacy by design is good for Patients and Drug development – Gilliosa Spurrier-Bernard (MelanomaFrance; Melanoma Patient Network Europe, FR)

Industry perspective – Bartek Madej (Novartis, CH)

Accessing clinical trials abroad. The experience of the Melanoma Patient Network Europe –Bettina Ryll (Melanoma Patient Network Europe, SE)

Cross-Border Access to Clinical Trials in the EU: results from an exploratory study – Teodora Lalova-Spinks (KU Leuven, BE)

Can we improve cross-border access to clinical trials? – Ingrid Klingmann (Chairman at Board of the European Forum for Good Clinical Practice, BE)